Business
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan’s effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27, 2024. Presentations will include new data from the SPARTAN Study highlighting efficacy and safety results of FILSPARI (sparsentan) in IgA nephropathy (IgAN) when used as a first-line treatment in newly diagnosed IgAN patients, an analysis from the PROTECT Study examining the clinical benefit of FILSPARI in IgAN regardless of participants’ baseline proteinuria, as well as patient-reported outcomes from the PROTECT and DUPLEX Studies. The Company will also present new data from the SPARTACUS Study, PROTECT open label extension, and real-world clinical experience of FILSPARI in IgAN demonstrating improvements in proteinuria reduction along with safety and efficacy data of sparsentan when used in combination with SGLT2 inhibitors. The late-breaking presentation is a post hoc analysis of outcomes of participants with genetic focal segmental glomerulosclerosis (gFSGS) from the DUPLEX Study. “We look forward to presenting data from a growing body of evidence supportive of the clinical benefit in IgAN that FILSPARI can provide when used as a first-line treatment and in combination with other therapies,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We’re also looking forward to presenting additional subgroup analyses from sparsentan in FSGS, where we will present data from a small group of high-risk patients with genetic FSGS, one of the most resistant to treatment.” You can find more information on Travere’s presence at ASN here. Late-Breaking Presentation Outcomes of the DUPLEX Trial in Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS)Poster: TH-PO1199Session: Late-Breaking Science PostersExhibit Hall; October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT Oral P...